argenx presents data broadening VYVGART use in MG and CIDP; pipeline advances
- ADAPT OCULUS: ocular MG scores deepened with more VYVGART cycles (AChR‑Ab‑positive −4.5 to −6.8; triple‑seronegative −2.7 to −4.5).
- ADAPT SERON one‑year: anti‑AChR antibody‑negative generalized MG maintained ~5‑point MG‑ADL improvements through Week 52; German registry shows higher burden in seronegative patients (MG‑ADL 6.9 vs 4.8).
- Real‑world analysis (>1,100 US MG patients) found greatest gains when VYVGART started earlier: within 1 year a 4.7‑point MG‑ADL reduction at 3 months vs 3.5 points if treated >3 years after diagnosis; 50% reached minimal symptom expression (p<0.001).
- CIDP: ADHERE/ADHERE+ show consistent safety with >5 years follow‑up and ~40% of responders reaching INCAT 0–1; grip‑strength decline risk reduced 71.5% (HR 0.285); Phase 4 one‑week IVIg→Hytrulo switch kept 87% on treatment at 12 weeks.
Conference scope
argenx presented clinical, long‑term and real‑world data for VYVGART (IV and Hytrulo SC) at AANEM and MGFA (Orlando, Sept 29–Oct 2, 2026), covering myasthenia gravis (MG), chronic inflammatory demyelinating polyneuropathy (CIDP) and updates on empasiprubart and adimanebart.
Myasthenia gravis
ADAPT OCULUS showed ocular MG improvements continued to deepen with additional VYVGART cycles: mean MGII ocular scores moved from −4.5 to −6.8 in AChR‑Ab‑positive and −2.7 to −4.5 in triple‑seronegative patients. ADAPT SERON one‑year data reported sustained efficacy and consistent safety in anti‑AChR antibody‑negative generalized MG, with mean MG‑ADL improvements of ~5 points maintained through Week 52. The German Myasthenia Gravis Registry analysis found higher disease burden in seronegative patients (mean MG‑ADL 6.9 vs 4.8).
A real‑world analysis of >1,100 US MG patients showed improvements across cohorts, with the largest benefit when treatment began earlier: patients treated within a year of diagnosis had a mean MG‑ADL reduction of 4.7 points at three months versus 3.5 points for those treated >3 years after diagnosis, and 50% reached minimal symptom expression (p<0.001).
CIDP findings
Interim ADHERE/ADHERE+ analyses reinforce a consistent safety profile for VYVGART Hytrulo with follow‑up beyond five years; about 40% of responders reached INCAT 0–1. A post‑hoc analysis showed a 71.5% reduction in relative risk of grip‑strength deterioration (HR 0.285; p<0.001), with earlier detection via grip strength. A Phase 4 switch study supports a one‑week transition from IVIg to Hytrulo, with 87% of patients remaining on Hytrulo through 12 weeks. In treatment‑naïve CIDP patients, 87.5% showed confirmed clinical improvement and 44.4% improved ≥2 INCAT points by Week 36 of ADHERE+.
Pipeline progress
Phase 2 ARDA+ data for empasiprubart in multifocal motor neuropathy (MMN) showed sustained clinical benefit and consistent safety, supported by translational evidence on pathway‑selective complement blockade. A Phase 1b study of adimanebart in DOK7‑CMS reported in‑clinic and real‑world improvements in walking measured by digital gait outcomes, informed by patient interviews.
Source: argenx